Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 1267 | 2649 | 48.5 | 93% |
Classes in level above (level 2) |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | CXCR4 | Author keyword | 364 | 41% | 26% | 685 |
| 2 | CXCR7 | Author keyword | 171 | 81% | 4% | 104 |
| 3 | CXCL12 | Author keyword | 159 | 50% | 9% | 232 |
| 4 | SDF 1 | Author keyword | 111 | 43% | 7% | 198 |
| 5 | STROMAL CELL DERIVED FACTOR 1 | Author keyword | 38 | 40% | 3% | 74 |
| 6 | MYELOKATHEXIS | Author keyword | 32 | 88% | 1% | 15 |
| 7 | AMD3100 | Author keyword | 23 | 40% | 2% | 45 |
| 8 | CXCR4 ANTAGONISTS | Author keyword | 21 | 78% | 1% | 14 |
| 9 | SDF 1 ALPHA | Author keyword | 21 | 33% | 2% | 52 |
| 10 | CHEMOKINE RECEPTOR | Author keyword | 21 | 16% | 5% | 122 |
Web of Science journal categories |
Author Key Words |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | CXCR4 | 364 | 41% | 26% | 685 | Search CXCR4 | Search CXCR4 |
| 2 | CXCR7 | 171 | 81% | 4% | 104 | Search CXCR7 | Search CXCR7 |
| 3 | CXCL12 | 159 | 50% | 9% | 232 | Search CXCL12 | Search CXCL12 |
| 4 | SDF 1 | 111 | 43% | 7% | 198 | Search SDF+1 | Search SDF+1 |
| 5 | STROMAL CELL DERIVED FACTOR 1 | 38 | 40% | 3% | 74 | Search STROMAL+CELL+DERIVED+FACTOR+1 | Search STROMAL+CELL+DERIVED+FACTOR+1 |
| 6 | MYELOKATHEXIS | 32 | 88% | 1% | 15 | Search MYELOKATHEXIS | Search MYELOKATHEXIS |
| 7 | AMD3100 | 23 | 40% | 2% | 45 | Search AMD3100 | Search AMD3100 |
| 8 | CXCR4 ANTAGONISTS | 21 | 78% | 1% | 14 | Search CXCR4+ANTAGONISTS | Search CXCR4+ANTAGONISTS |
| 9 | SDF 1 ALPHA | 21 | 33% | 2% | 52 | Search SDF+1+ALPHA | Search SDF+1+ALPHA |
| 10 | CHEMOKINE RECEPTOR | 21 | 16% | 5% | 122 | Search CHEMOKINE+RECEPTOR | Search CHEMOKINE+RECEPTOR |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | CHEMOKINE RECEPTOR CXCR4 | 480 | 48% | 28% | 742 |
| 2 | SDF 1 | 176 | 49% | 10% | 263 |
| 3 | CHEMOKINE RECEPTOR CXCR7 | 118 | 95% | 1% | 39 |
| 4 | CELL DERIVED FACTOR 1 | 103 | 66% | 4% | 97 |
| 5 | LYMPHOCYTE CHEMOATTRACTANT | 96 | 57% | 4% | 112 |
| 6 | CXCL12 | 90 | 61% | 4% | 96 |
| 7 | CXCR4 | 78 | 24% | 11% | 280 |
| 8 | RDC1 | 62 | 90% | 1% | 27 |
| 9 | T140 | 51 | 91% | 1% | 21 |
| 10 | RECEPTOR CXCR4 | 49 | 41% | 4% | 95 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references | % act. ref. to same field |
|---|---|---|---|---|
| A review on CXCR4/CXCL12 axis in oncology: No place to hide | 2013 | 100 | 65 | 60% |
| Expression of CXCR4 and breast cancer prognosis: a systematic review and meta-analysis | 2014 | 17 | 29 | 90% |
| CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment | 2006 | 585 | 84 | 69% |
| Chemokine receptor-specific antibodies in cancer immunotherapy: achievements and challenges | 2015 | 3 | 252 | 42% |
| CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression | 2010 | 178 | 129 | 72% |
| Homeostatic chemokine receptors and organ-specific metastasis | 2011 | 125 | 115 | 52% |
| CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers | 2009 | 184 | 137 | 59% |
| Cancer and the chemokine network | 2004 | 981 | 95 | 48% |
| The chemokine system and cancer | 2012 | 88 | 59 | 44% |
| The Role of chemokine receptor CXCR4 in breast cancer metastasis | 2013 | 40 | 53 | 60% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | STEM CELL BIOL PROGRAM | 7 | 23% | 1.0% | 27 |
| 2 | U819 | 6 | 48% | 0.4% | 10 |
| 3 | EUROPEAN STEM CELL THER EUT EXCELLENCE | 6 | 71% | 0.2% | 5 |
| 4 | UNITE IMMUNOL VIRALE | 4 | 22% | 0.6% | 17 |
| 5 | REGENERAT REPARAT MED | 3 | 38% | 0.2% | 6 |
| 6 | CBS EDMONTON | 3 | 60% | 0.1% | 3 |
| 7 | EXCELLENCE MEDICAT INNOVAT THER EUT | 3 | 60% | 0.1% | 3 |
| 8 | UMR S996 | 3 | 35% | 0.2% | 6 |
| 9 | MED SYST CONTROL | 3 | 30% | 0.3% | 7 |
| 10 | IMMUNOBIOL HEMATOL | 2 | 24% | 0.3% | 8 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000142905 | CCL20//CCR6//MACROPHAGE INFLAMMATORY PROTEIN 3 ALPHA |
| 2 | 0.0000117932 | CXCL14//DBC2//BRAK |
| 3 | 0.0000084855 | LYMPHOTACTIN//CTAP III//CHEMOKINE STRUCTURE |
| 4 | 0.0000084002 | DUFFY BLOOD GROUP//DARC//DUFFY ANTIGEN |
| 5 | 0.0000078285 | CXCR3//CXCL10//CXCL9 |
| 6 | 0.0000076933 | IMMUNOBIOL ROBERT H LURIE CANC//EXPT CLIN NEUROL//MS CLIN |
| 7 | 0.0000072922 | FRACTALKINE//CXCL16//CX3CR1 |
| 8 | 0.0000072660 | HEMATOPOIETIC STEM CELL//SAKAGUCHI DEV BIOLSHINJUKU KU//SAKAGUCHI DEV BIOL |
| 9 | 0.0000071769 | CCR5//MARAVIROC//CCR5 ANTAGONIST |
| 10 | 0.0000070791 | CCR2 ANTAGONIST//CCR2//CCR2 ANTAGONISTS |